01 February 2004
G-CSF in solid tumor chemotherapy: a tailored regimen reduces febrile neutropenia, treatment delays and direct costs
Nicolas Tsavaris, Christos Kosmas, Panagiotis Gouveris, Maria Vadiak, Antonis Dimitrakopoulos, Dimitra Karadima, Efterpi Pagouni, George Panagiotakopoulos, Evanthia Tzima, Sevasti Ispoglou, Dimitris Sakelariou, Christos KoufosMed Sci Monit 2004; 10(2): PI24-28 :: ID: 11583
Abstract
Background:Current guidelines do not recommend G-CSF for patients with risk factors for neutropenia.Material/Methods: One-hundred patients undergoing chemotherapy were randomized to treatment with G-CSF at 5 Kg/kg for established febrile neutropenia (ANC <1000/micro l) (Group A) or G-CSF at 263 Kg/day if ANC was 1500/micro l or less on the day of the expected nadir, with the duration of treatment determined by the severity of neutropenia (Group B).
Results: The number of doses of G-CSF was similar in the two groups. There were 34 cases of febrile neutropenia in Group A, but none in Group B (p=0.0001). Hospital admission for febrile neutropenia, antibiotic use and delays in chemotherapy were all significantly more common in Group A. Total direct costs were estimated to be € 66, 646 for Group A and € 47, 119 for Group B.
Conclusions: Tailoring treatment does not increase G-CSF use, but significantly reduces febrile neutropenia and treatment delays and lowers direct costs.
Keywords: Antineoplastic Combined Chemotherapy Protocols - administration & dosage, Antineoplastic Combined Chemotherapy Protocols - economics, Drug Administration Schedule, Fever - blood, Fever - complications, Fever - drug therapy, Granulocyte Colony-Stimulating Factor - administration & dosage, Granulocyte Colony-Stimulating Factor - economics, Leukocyte Count, Neoplasms - blood, Neoplasms - complications, Neoplasms - drug therapy, Neutropenia - blood, Neutropenia - complications, Neutropenia - drug therapy, Neutrophils - cytology, Neutrophils - drug effects, Antineoplastic Combined Chemotherapy Protocols - economics, Drug Administration Schedule, Fever - drug therapy, Granulocyte Colony-Stimulating Factor - economics, Leukocyte Count, Neoplasms - drug therapy, Neutropenia - drug therapy, Neutrophils - drug effects
883 20
Editorial
01 December 2023 : Editorial
Editorial: Outbreaks of Post-Pandemic Childhood Pneumonia and the Re-Emergence of Endemic Respiratory InfectionsDOI: 10.12659/MSM.943312
Med Sci Monit 2023; 29:e943312
In Press
01 Dec 2023 : Clinical Research
Risk Factors and Clinical Outcomes of COVID-19 Infection in Multiple Sclerosis Patients: A Retrospective St...Med Sci Monit In Press; DOI:
30 Nov 2023 : Review article
Decoding the Neurological Sequelae of General Anesthesia: A ReviewMed Sci Monit In Press; DOI:
30 Nov 2023 : Clinical Research
Enhanced Pain Relief and Muscle Growth in Individuals with Low Back Instability: The Impact of Blood Flow R...Med Sci Monit In Press; DOI:
29 Nov 2023 : Clinical Research
Comparative Analysis of Intramedullary Nail versus Plate Fixation for Fibula Fracture in Supination Externa...Med Sci Monit In Press; DOI:
Most Viewed Current Articles
13 Nov 2021 : Clinical Research
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292